Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Flexion Therapeutics shares have dropped 37% since the beginning of the year. Adventurous. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Want to see which stocks are moving? Get short term trading ideas from the MarketBeat Idea Engine. 11/06: FLEXION THERAPEUTICS: Reports Inducement Grants Under Nasdaq Listing Rule 5635(.. AQ. Wells Fargo & Company MN Sells 3,651 Shares of NorthWestern Co. (NYSE:NWE) » NEXT . 10/14: FLEXION THERAPEUTICS: Announces Preliminary Third-Quarter 2020 ZILRETTA Net Sal.. AQ. Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. BURLINGTON, Mass. News. Adventurous. BURLINGTON, Mass. * Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $23.7 million in third quarter 2020 BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30, 2020.“Throughout the third quarter, we saw … View which stocks are hot on social media with MarketBeat's trending stocks report. Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 4.92% and -4.12%, respectively, for the quarter ended June 2018. Recent executive movements at Flexion Therapeutics. Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis, at the American Society of Gene & Cell Therapy Annual Meeting finance.yahoo.com - May 5 at 11:43 AM The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. The FLXN stock was last observed hovering at around $13.01 in the last trading session, with the day’s gains setting it 0.16% off its average median price target of $20.00 for the next 12 months. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. Elizabeth Kwo has joined the company as Director (news posted on August 20 2020). But FLXN stock started tumbling at the beginning of the year.Source: Shutterstock And despite positive news about its flagship drug, Zilretta, it's struggling to reclaim its gains.There's a reason for that. FX201 (humantakinogene hadenovec) FX201 is a novel, intra-articular gene therapy product candidate which utilizes a helper-dependent adenovirus (HDAd) vector based on human serotype 5 (Ad5) that is designed to transfer a … Flexion Therapeutics hasn't issued any revenue guidance for the time being. Share Price & News. Company's 52-week low was at $5.01 Flexion Therapeutics sees Q2 Zilretta sales of $15.4M, Flexion Therapeutics Announces Preliminary Second-Quarter 2020 ZILRETTA® Net Sales. All rights reserved. Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. FLEXION THERAPEUTICS, INC. : News, information and stories for FLEXION THERAPEUTICS, INC. | Nasdaq: FLXN | Nasdaq Flexion’s strategy is to build a robust pipeline of locally administered therapies to address musculoskeletal conditions, with an initial focus on osteoarthritis (OA). In the final minutes of trading on Wednesday, shares hit $12.97, a decline of 26% in the last 12 months. Date Time Source Headline; 20/8/2020: 21:48: EDGAR: Statement of Changes in Beneficial Ownership (4) 20/8/2020: 21:46: EDGAR: Initial Statement of Beneficial Ownership (3) 19/8/2020: 22:01: EDGAR: Current Report Filing (8-k) 19/8/2020: 14:00: GLOBE : Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board … Learn more. View detailed financial information, real-time news, videos, quotes and analysis on Flexion Therapeutics, Inc. (NASDAQ:FLXN). 11/09: FLEXION THERAPEUTICS: Reports Inducement Grants under Nasdaq Listing Rule 5635: AQ. Flexion Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions. Flexion (FLXN) Soars: Stock Adds 6.6% in Session, Planning For A Rebound In Flexion Therapeutics, Why Flexion Therapeutics Is Tumbling 10% Today, Flexion under pressure after pricing equity offering, Flexion Therapeutics Announces Pricing of Public Offering of Common Stock, Flexion Therapeutics Announces Proposed Public Offering of Common Stock, How Flexion Therapeutics (FLXN) Stock Stands Out in a Strong Industry, Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference, Flexion Therapeutics Inc (FLXN) Q1 2020 Earnings Call Transcript, Edited Transcript of FLXN earnings conference call or presentation 7-May-20 8:30pm GMT, Receive Analysts' Upgrades and Downgrades Daily. Create an alert to follow the executive moves at Flexion Therapeutics. Flexion’s strategy is to build a robust pipeline of locally administered therapies to address musculoskeletal conditions, with an initial focus on osteoarthritis (OA). for-phone-only for-tablet-portrait-up for-tablet-landscape-up for-desktop-up for-wide-desktop-up After the company reported it had priced its common share offering at $9.75 per share, shares in Flexion Therapeutics (NASDAQ: FLXN) are trading 10% lower at 11:30 a.m. EST on Thursday. Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights finance.yahoo.com - August 5 at 6:35 PM: Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020 finance.yahoo.com - July 30 at 5:55 PM: Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know Flexion Therapeutics News. How has Flexion Therapeutics's share price performed over time and what events caused price changes? Comparing Flexion Therapeutics, Inc.'s CEO Compensation With the industry. Do Not Sell My Information. FLXN - Flexion Therapeutics Inc Share News. Most relevant news about FLEXION THERAPEUTICS, INC. 10/29: FLEXION THERAPEUTICS: to Report Third-Quarter 2020 Financial Results on Novembe.. AQ. Find the latest Flexion Therapeutics, Inc. (FLXN) stock discussion in Yahoo Finance's forum. Flexion Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $23.66 million for the quarter ended September 2020, surpassing the … Flexion Therapeutics (FLXN) Reports Q2 Loss, Misses Revenue Estimates, Flexion Therapeutics EPS misses by $0.07, misses on revenue, Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights, Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020, Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Identify stocks that meet your criteria using seven unique stock screeners. 11.35 0.00 (0.00%)After hours: 4:24PM EST, Subscribe to Premium to view Fair Value for FLXN. Recent Stock Performance. Year-to-date, Flexion Therapeutics Inc (NASDAQ: FLXN ) stock lost 42.1% … Find the latest news headlines from Flexion Therapeutics, Inc. Common Stock (FLXN) at Nasdaq.com. $11.82 -0.2 -1.7% Last Trade - 11/09/20. View our full suite of financial calendars and market data tables, all for free. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Export data to Excel for your own analysis. The company has a product that addresses a condition that affects a growing number of Americans. Why Flexion Therapeutics Is Tumbling 10% Today. 11/06: Flexion Therapeutics Reports Inducement Grants … Get prepared with the key expectations. (AP) _ Flexion Therapeutics Inc. (FLXN) on Wednesday reported a loss of $24.6 million in its third quarter.On a per-share basis, the Burlington, Massachusetts-based company said it had a loss of 50 cents.The results did not meet Wall Street expectations. Looking at the stock we see that its previous close was $11.74 and the beta (5Y monthly) reads 1.79 with the … Flexion resumed enrollment in Phase 1 dose-escalation trial for FX201; FX301 on track to enter clinic in 2021; BURLINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for … Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million Provided by GlobeNewswire Oct 13, 2020 10:59 AM UTC GlobeNewswire Flexion Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). BURLINGTON, Mass. Flexion Therapeutics (FLXN) News Headlines. Researching Flexion Therapeutics (NASDAQ:FLXN) stock? MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Flexion Therapeutics (FLXN) In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Flexion Therapeutics, with a price target of $25.00. 10/29: Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on Novemb.. GL. 10/13: FLEXION THERAPEUTICS: Announces Preliminary … The company’s shares closed last Friday at $10.82. BURLINGTON, Mass. Our data indicates that Flexion Therapeutics, Inc. has a market capitalization of US$615m, and total annual CEO compensation was reported as US$3.8m for the year to December 2019. View our latest analysis for Flexion Therapeutics . All news about FLEXION THERAPEUTICS, INC. 11/19: FLEXION THERAPEUTICS INC: Results of Operations and Financial Condition (form 8.. AQ. Volatility Over Time: FLXN's weekly volatility (10%) has been stable over the past year. Distributed by Public, unedited and … Latest Share Price and Events. Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) YAHOO!News 3 days ago Why Flexion Therapeutics (FLXN) Stock is a Compelling Investment Case BURLINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright Virtual Healthcare Conference. Learn everything you need to know about successful options trading with this three-part video course. $11.29 0.6 5.4% Last Trade - 5:35pm. Is Flexion Therapeutics (FLXN) a Smart Long-term Buy? Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. View the latest FLXN financial statements, income statements and financial ratios. Flexion shares halted on news of FDA approval for knee pain injection Oct. 6, 2017 at 3:10 p.m. Flexion Therapeutics (NASDAQ:FLXN) gets FDA approval for a supplemental New Drug Application to update the product label for Zilretta (triamcinolone aceton Sector Healthcare RiskRating. Latest Share Price and Events. Learn more. © American Consumer News, LLC dba MarketBeat® 2010-2020. Please log in to your account or sign up in order to add this asset to your watchlist. A high-level overview of Flexion Therapeutics, Inc. (FLXN) stock. This compares to loss of $1 per share a year ago. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. Share your opinion and gain insight from other stock traders and investors. Aging of America is a Catalyst for Flexion Therapeutics; FLXN has been the subject of several other reports. Press Releases. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGM - NasdaqGM Real Time Price. Shareholders might have noticed that Flexion Therapeutics, Inc. (NASDAQ:FLXN) filed its quarterly result this time... Wall Street legend Whitney Tilson says there's a huge new tech trend coming – and he's revealing his #1 pick for free. for-phone-only for-tablet-portrait-up for-tablet-landscape-up for-desktop-up for-wide-desktop-up and is actively exploring opportunities to augment our pipeline through partnering. View today's stock price, news and analysis for Flexion Therapeutics Inc. (FLXN). On a per-share basis, the Burlington, Massachusetts-based company said it had a loss of 50 cents. FLXN - Flexion Therapeutics Inc Reuters News. Flexion Therapeutics News: This is the News-site for the company Flexion Therapeutics on Markets Insider Flexion Therapeutics, Inc. (FLXN) is trading 153.09% from its 52 week low and -44.82% from its 52 week high. Read More It offers products under the Zilretta brand. Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference. Overview; News; Financials; Chart; GlobeNewsWire - 2 weeks ago. Fundamental company data provided by Morningstar and Zacks Investment Research. This is yet another view into Flexion Therapeutics filtered headlines to help investors concentrate on Flexion Therapeutics noise-free news that matters.The value of Net Income Common Stock is estimated to slide to about (153.7 M). BURLINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in the second cohort of the Phase 1 dose-escalation trial evaluating the safety and tolerability of FX201, an investigational, intra-articular, IL-1Ra gene therapy product candidate being developed for the treatment of osteoarthritis (OA). BURLINGTON, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has entered into an exclusive license agreement with HK Tainuo and Jiangsu Tainuo (a subsidiary of China Shijiazhuang Pharmaceutical Co, Ltd.) for the development and commercialization of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in … Flexion Therapeutics Inc. (NASDAQ: FLXN) is -37.15% lower on its value in year-to-date trading and has touched a low of $5.01 and a high of $22.98 in the current 52-week trading range. Get daily stock ideas top-performing Wall Street analysts. Flexion Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference. To see all exchange delays and terms of use please see disclaimer.
Benq Projector Flickering Problem, Makita Drs780z Review, Shiva Eye Agate Benefits, Shoe Discount Websites, Caterpillar To Butterfly National Geographic Read Aloud, Cept University Ranking, Internal Body Parts Pictures With Name, Use Case Diagram For Student Management System,
